DE69526973D1 - Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel - Google Patents

Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel

Info

Publication number
DE69526973D1
DE69526973D1 DE69526973T DE69526973T DE69526973D1 DE 69526973 D1 DE69526973 D1 DE 69526973D1 DE 69526973 T DE69526973 T DE 69526973T DE 69526973 T DE69526973 T DE 69526973T DE 69526973 D1 DE69526973 D1 DE 69526973D1
Authority
DE
Germany
Prior art keywords
sequences
therapeutic
hepatitis
preventive
diagnostic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69526973T
Other languages
English (en)
Other versions
DE69526973T2 (de
DE69526973T3 (de
Inventor
Geert Maertens
Lieven Stuyver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26137782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69526973(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of DE69526973D1 publication Critical patent/DE69526973D1/de
Publication of DE69526973T2 publication Critical patent/DE69526973T2/de
Application granted granted Critical
Publication of DE69526973T3 publication Critical patent/DE69526973T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE69526973T 1994-10-21 1995-10-23 Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel Expired - Lifetime DE69526973T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP94870166 1994-10-21
EP94870166 1994-10-21
EP95870076 1995-06-28
EP95870076 1995-06-28
PCT/EP1995/004155 WO1996013590A2 (en) 1994-10-21 1995-10-23 New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents

Publications (3)

Publication Number Publication Date
DE69526973D1 true DE69526973D1 (de) 2002-07-11
DE69526973T2 DE69526973T2 (de) 2003-01-02
DE69526973T3 DE69526973T3 (de) 2010-01-07

Family

ID=26137782

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526973T Expired - Lifetime DE69526973T3 (de) 1994-10-21 1995-10-23 Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel

Country Status (12)

Country Link
US (2) US7129337B1 (de)
EP (2) EP0804584B2 (de)
JP (2) JPH10507643A (de)
AT (1) ATE218617T1 (de)
AU (1) AU702436B2 (de)
BR (1) BR9509421A (de)
CA (1) CA2201703A1 (de)
DE (1) DE69526973T3 (de)
DK (1) DK0804584T3 (de)
ES (1) ES2176342T5 (de)
PT (1) PT804584E (de)
WO (1) WO1996013590A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620075D0 (en) * 1996-09-26 1996-11-13 Dynal As Method
US7078500B1 (en) * 1998-01-30 2006-07-18 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis C virus
PL343469A1 (en) 1998-04-17 2001-08-13 Innogenetics Nv Improved immunodiagnostic assays using reducing agents
AU4497999A (en) * 1998-04-28 1999-11-16 Ingrid-Corina Bergter Radioimmunopharmaca for treating hepatitis c
WO1999067285A1 (en) * 1998-06-24 1999-12-29 Innogenetics N.V. Particles of hcv envelope proteins: use for vaccination
AU2001292151B2 (en) * 2000-08-17 2006-05-04 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
US8124747B2 (en) * 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
CN1977050B (zh) 2004-01-07 2012-09-05 第三次浪潮技术公司 丙型肝炎病毒基因型的确定
RU2267496C2 (ru) * 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды
EP1888751A2 (de) * 2005-05-25 2008-02-20 Tripep Ab Nichtstrukturelles ns3/4a-fusionsgen des hepatitis-c-virus
US7465561B2 (en) 2005-06-30 2008-12-16 Roche Molecular Systems, Inc. Probes and methods for hepatitis C virus typing using single probe analysis
PL2361638T3 (pl) 2005-12-12 2014-08-29 Ac Immune Sa Przeciwciała monoklonalne swoiste wobec A beta 1-42 o właściwościach terapeutycznych
AU2007275467B2 (en) 2006-07-14 2013-12-05 Ac Immune S.A. Humanized antibody against amyloid beta
KR20160049045A (ko) 2006-07-14 2016-05-04 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
CA2661814A1 (en) * 2006-08-25 2008-02-28 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Recombinant hcv e2 glycoprotein
WO2008046923A2 (en) 2006-10-20 2008-04-24 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
EP2463390A1 (de) 2006-10-20 2012-06-13 Innogenetics N.V. Methodik zur Analyse von Sequenzvariationen innerhalb des HCV-NS5B-Genombereichs
CA2670418A1 (en) 2006-11-24 2008-05-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's
BRPI0812484A2 (pt) 2007-06-12 2018-06-05 Ac Immune Sa anticorpo monoclonal, regiões variáveis de cadeia leve e de cadeia pesada, cdr isolada, polinucleotídeo, composição terapêutica, métodos para tratar doenças e distúrbios, para produzir um anticorpo, para tratar ou aliviar os efeitos de doenças e distúrbios, para reduzir a carga de placas no cérebro de um indivíduo, para reduzir a quantidade de placas no cérebro de um indivíduo, para diminuir a quantidade total de abeta solúvel no cérebro de um indivíduo, para reter ou aumentar a capacidade de memória cognitiva em um indivíduo, de diagnose de ou para diagnosticar uma predisposição para uma doença associada com amilóide ou condição em um paciente, para determinar a extensão de carga de placa amiloidogênica em um tecido de um indivíduo, para monitorar doença residual mínima em um indivíduo e para prever responsividade de um indivíduo, linhagem de células, kit de teste, epítopo abeta
US20090155249A1 (en) 2007-06-12 2009-06-18 Ac Immune S.A. Humanized antibody igg1
EP2236624B1 (de) * 2007-08-09 2012-11-07 Federalnoe Gosudarstvennoe Byudzhetnoe Uchrezhdenie Nauki Institut Molekulyarnoi Biologi Im. V.A. Engelgardta Rossiiskoi Akademii Nauk Verfahren zur identifizierung des genotyps und subtyps von hepatitis-c-virus auf einem biologischen mikrochip
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
SG178809A1 (en) 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
EP2311823A1 (de) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridinverbindungen zur Behandlung von Krankheiten im Zusammenhang mit Amyloidproteinen oder zur Behandlung von Augenkrankheiten
EP2377860A1 (de) 2010-04-16 2011-10-19 AC Immune S.A. Neuartige Verbindungen zur Behandlung von Krankheiten im Zusammenhang mit Amyloid- oder amyloidähnlichen Proteinen
CN102939282B (zh) 2010-04-16 2015-12-02 Ac免疫有限公司 用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物
US8962241B2 (en) * 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
BR112013002297A2 (pt) 2010-07-30 2016-05-24 Ac Immune Sa anticorpos humanizados seguros e funcionais
TW201216985A (en) 2010-10-07 2012-05-01 Ac Immune Sa Pharmaceutical composition
EP2632434A1 (de) 2010-10-26 2013-09-04 AC Immune S.A. Konstrukt auf liposomenbasis mit einem anhand von hydrophoben einheiten modifizierten peptid
CN104080806B (zh) 2011-10-07 2018-01-19 Ac免疫有限公司 识别Tau的磷酸化特异抗体
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CN102766701B (zh) * 2012-07-04 2016-05-04 福州泰普生物科学有限公司 丙型肝炎病毒基因分型的试剂盒及方法
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
BR112015023262B8 (pt) 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
US9891225B2 (en) * 2013-05-10 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for simultaneous detection of HCV antigen/antibody
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
NZ717671A (en) 2013-09-05 2022-07-01 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
KR102511343B1 (ko) 2015-03-05 2023-03-17 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) 및 항체
EP3472197A1 (de) 2016-06-15 2019-04-24 Sutro Biopharma, Inc. Antikörper mit manipulierten ch2-domänen, zusammensetzungen davon und verfahren zur verwendung davon
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
US20230173021A1 (en) 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
EP3943097A1 (de) 2020-07-24 2022-01-26 AB2 Bio SA Car-t-zelltherapie
WO2023166206A1 (en) 2022-03-04 2023-09-07 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas
WO2024006563A1 (en) 2022-07-01 2024-01-04 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT54896A (en) 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
WO1991004262A1 (en) 1989-09-15 1991-04-04 National Institute Of Health Of Japan New hcv isolates
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
ES2029171A6 (es) 1989-12-18 1992-07-16 Wellcome Found Un procedimiento para preparar un polipeptido virico de hepatitis no a y no b post-transfusional (pt-nanbh)
FI913068A (fi) 1990-06-25 1991-12-26 Univ Osaka Res Found Non-a-, non-b-hepatitisviruspartiklar.
DK0585398T3 (da) 1991-05-08 2004-02-02 Chiron Corp HCV genomiske sekvenser til diagnostiske og terapeutiske midler
RU2148587C1 (ru) * 1991-06-24 2000-05-10 Чирон Корпорейшн Полипептид и способ его получения, реагент для иммуноанализа, способ определения присутствия антител и способ индукции иммунного ответа
EP0532167A3 (en) 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
PL171972B1 (pl) * 1991-09-13 1997-07-31 Chiron Corp Sposób wytwarzania polipeptydu HCV PL
AU671967B2 (en) 1991-11-21 1996-09-19 Common Services Agency Hepatitis-C virus testing
ATE552340T1 (de) * 1993-04-27 2012-04-15 Innogenetics Nv Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismitteln
JPH06319563A (ja) * 1993-05-13 1994-11-22 Imuno Japan:Kk Ｃ型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにｃ型 肝炎ウイルス遺伝子型判定方法
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines

Also Published As

Publication number Publication date
ATE218617T1 (de) 2002-06-15
DE69526973T2 (de) 2003-01-02
DK0804584T3 (da) 2002-09-23
BR9509421A (pt) 1997-09-30
PT804584E (pt) 2002-11-29
EP0804584A1 (de) 1997-11-05
EP1076092A3 (de) 2001-03-28
WO1996013590A3 (en) 1996-08-15
EP0804584B1 (de) 2002-06-05
AU702436B2 (en) 1999-02-18
EP1076092A2 (de) 2001-02-14
US20020183508A1 (en) 2002-12-05
US6974864B2 (en) 2005-12-13
DE69526973T3 (de) 2010-01-07
US7129337B1 (en) 2006-10-31
JP2005118044A (ja) 2005-05-12
JPH10507643A (ja) 1998-07-28
WO1996013590A2 (en) 1996-05-09
ES2176342T5 (es) 2010-02-09
EP0804584B2 (de) 2008-07-09
ES2176342T3 (es) 2002-12-01
CA2201703A1 (en) 1996-05-09
AU3844095A (en) 1996-05-23

Similar Documents

Publication Publication Date Title
DE69526973T2 (de) Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel
ATE373093T1 (de) Sequenzen der genotype des hepatitis-c-virus sowie ihre verwendung als arzneimitteln und diagnostika
DE69334357D1 (de) Nachweis und Typisierung das Hepatitis C Virus (HCV) mittels 5'UTR und NS5 Nukleinsäuresequenzen
FI924396A0 (fi) Diagnostiska aemnen.
DE3885613T2 (de) Schutzkleidung gegen chemische und biologische mittel.
ATE182180T1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
ATE426333T1 (de) Verwendung bestimmter copolymere als adjuvans und mittel fur den agrotechnischen bereich
DE59505470D1 (de) Verwendung von im IR-Bereich absorbierenden und fluoreszierenden Verbindungen als Riss-Prüfmittel
DE59010919D1 (de) N- und O-substituierte Aminophenolderivate, Zwischenprodukte zu deren Herstellung, deren Verwendung als Hydrolasesubstrate, ein entsprechendes Bestimmungsverfahren und hierfür geeignetes diagnostisches Mittel
DE69637715D1 (de) Synthetische säugetier alpha-n-acetylglukosaminidase und dafür kodierende genetische sequenzen
DE60029327D1 (de) Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
ATE389021T1 (de) Rrekombinante proteine eines pakistani-stammes von hepatitis-e-virus, ihre verwendung in diagnotischen verfahren und als impfstoff
ATE154134T1 (de) Nachweis, quantifizierung und klassifizierung von ras-proteinen in körperflüssigkeiten und geweben
ATE242883T1 (de) Verfahren zur bestimmung von blutgerinnungsfaktoren viii und ix
DE69900283T2 (de) Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment
DE69026868D1 (de) DNS-Probe zum Nachweis vom Human-Parainfluenza-Typ-2-Virus
ATE119291T1 (de) Verfahren zur bestimmung von antikörpern gegen erreger von infektionskrankheiten in körperflüssigkeiten, mittel dazu und ihre verwendung in diesem verfahren.
DE19580096T1 (de) Verfahren und Mittel für eine innere Abtötung von Bakterien und Viren in zahnärztlichen Instrumenten
DE68914840T2 (de) Verwendung von castanospermin als ein antientzündliches und immununterdrückendes mittel.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8332 No legal effect for de